Author

B. L. Szabolcs

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1 Organism:zebrafish· 1

Frequent Co-Authors

A. A. Ascsillan· 2 shared L. V. Kemeny· 2 shared A. Bartha· 1 shared A. I. T. Lakatos· 1 shared A. Kawakami· 1 shared A. M. McConnell· 1 shared A. Mueller· 1 shared A. Navarini· 1 shared

Activity by Year

2023-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. A. Ascsillan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Identifying Ferroptosis Inducers, HDAC, and RTK Inhibitor Sensitivity in Melanoma Subtypes through Unbiased Drug Target Prediction

I. Pla, B. L. Szabolcs, P. N. Peter, Z. Ujfaludi, Y. Kim, P. Horvatovich, A. Sanchez, K. Pawlowski, E. Wieslander, J. Guedes, D. M. Pal, A. A. Ascsillan, L. H. Betancourt, I. B. Nemeth, J. Gil, , L. V. Kemeny

This paper identifies potential drug targets and predicts treatment efficacy and resistance in melanoma subtypes using proteogenomic data and drug sensitivity analysis.

bioRxiv · Feb 8, 2024 · PreprintCancer Biology

MITF regulates IDH1 and NNT and drives a transcriptional program protecting cutaneous melanoma from reactive oxygen species

E. Roider, A. I. T. Lakatos, A. M. McConnell, P. Wang, A. Mueller, A. Kawakami, J. Tsoi, B. L. Szabolcs, A. A. Ascsillan, Y. Suita, V. Igras, J. A. Lo, J. J. Hsiao, R. Lapides, D. M. P. Pal, , D. E. Fisher

The paper shows MITF promotes melanoma survival by increasing resistance to reactive oxygen species through regulating antioxidant genes like IDH1 and NNT.

bioRxiv · Nov 10, 2023 · PreprintCancer Biology